Adding immunotherapy to chemotherapy for stage III colon cancer (dMMR) cuts the risk of recurrence or death by 50%. A landmark phase III trial finds that 86% of patients remained disease-free after 3 years, establishing a new global "standard of care" for this specific genetic subtype.
Read Full Article
#Immunotherapy #ColonCancer #dMMR
Read Full Article
#Immunotherapy #ColonCancer #dMMR
The New England Journal of Medicine
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer | NEJM
Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin
regimen. Whether the addition of atezolizumab (an anti–programmed death ligand 1 agent)
to ...
regimen. Whether the addition of atezolizumab (an anti–programmed death ligand 1 agent)
to ...